AstraZeneca PLC
AZNCFOTCHealthcare
$189.90
$-2.60(-1.35%)
Market Cap$294.4B
P/E Ratio—
52W High$209.48
52W Low$122.26
AstraZeneca PLC (AZNCF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
AZNCF · earnings · updated Jun 8, 2026
Latest Earnings
Q1 FY2026Report Date: Feb 10, 2026EPS Actual
$1.49
Revenue
$15.50B
Est. $15.44B · +0.4%
Fiscal Period
Q1 FY2026
FY ends December
Report Date
Feb 10, 2026
After Market Close
AZNCF reports quarterly as a OTC-listed Drug Manufacturers - General company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| — Q1 FY2026 | Feb 10, 2026 | — | $1.49 | — | $15.50B | $15.44B | +0.4% |
| ▼ Q4 FY2025 | Nov 6, 2025 | $2.29 | $1.62 | -29.3% | $15.19B | $15.41B | -1.4% |
| ▼ Q3 FY2025 | Jul 29, 2025 | $2.16 | $1.57 | -27.3% | $14.46B | $14.76B | -2.1% |
| ▼ Q2 FY2025 | Apr 29, 2025 | $2.23 | $1.92 | -13.9% | $13.59B | $14.06B | -3.3% |
| ▼ Q1 FY2025 | Feb 6, 2025 | $2.07 | $0.96 | -53.6% | $14.89B | $13.34B | +11.6% |
| ▼ Q4 FY2024 | Nov 12, 2024 | $2.04 | $0.92 | -55.1% | $13.56B | $13.08B | +3.7% |
| ▼ Q3 FY2024 | Jul 25, 2024 | $1.97 | $1.24 | -37.1% | $12.96B | $12.62B | +2.7% |
| ▼ Q2 FY2024 | Apr 25, 2024 | $1.91 | $1.40 | -26.7% | $12.62B | $11.80B | +7.0% |
Q1 FY2026
Feb 10, 2026
EPS Actual
$1.49
EPS Est.
—
EPS Surpr.
—
Revenue
$15.50B
Q4 FY2025
Nov 6, 2025Miss
EPS Actual
$1.62
EPS Est.
$2.29
EPS Surpr.
-29.3%
Revenue
$15.19B
Q3 FY2025
Jul 29, 2025Miss
EPS Actual
$1.57
EPS Est.
$2.16
EPS Surpr.
-27.3%
Revenue
$14.46B
Q2 FY2025
Apr 29, 2025Miss
EPS Actual
$1.92
EPS Est.
$2.23
EPS Surpr.
-13.9%
Revenue
$13.59B
Q1 FY2025
Feb 6, 2025Miss
EPS Actual
$0.96
EPS Est.
$2.07
EPS Surpr.
-53.6%
Revenue
$14.89B
Q4 FY2024
Nov 12, 2024Miss
EPS Actual
$0.92
EPS Est.
$2.04
EPS Surpr.
-55.1%
Revenue
$13.56B
Q3 FY2024
Jul 25, 2024Miss
EPS Actual
$1.24
EPS Est.
$1.97
EPS Surpr.
-37.1%
Revenue
$12.96B
Q2 FY2024
Apr 25, 2024Miss
EPS Actual
$1.40
EPS Est.
$1.91
EPS Surpr.
-26.7%
Revenue
$12.62B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $2.64 | $2.64 | $2.64 | 1 |
| Q3 FY2027 | $2.97 | $2.97 | $2.97 | 1 |
| Q2 FY2027 | $2.69 | $2.69 | $2.69 | 1 |
| Q1 FY2027 | $2.85 | $2.85 | $2.85 | 1 |
| Q4 FY2026 | $2.17 | $2.17 | $2.17 | 1 |
| Q3 FY2026 | $2.69 | $2.69 | $2.69 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $17.0B | $17.0B | $17.0B | 2 |
| Q3 FY2027 | $16.6B | $16.6B | $16.6B | 2 |
| Q2 FY2027 | $15.7B | $15.7B | $15.7B | 2 |
| Q1 FY2027 | $15.1B | $15.1B | $15.1B | 2 |
| Q4 FY2026 | $16.3B | $16.3B | $16.3B | 2 |
| Q3 FY2026 | $16.0B | $16.0B | $16.0B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q1 FY2026 | Feb 10, 2026 | — | $188.01 | $193.40 | +2.87% |
| ▼ Q4 FY2025 | Nov 6, 2025 | -29.3% | $165.26 | $169.00 | +2.26% |
| ▼ Q3 FY2025 | Jul 29, 2025 | -27.3% | $144.10 | $150.48 | +4.43% |
| ▼ Q2 FY2025 | Apr 29, 2025 | -13.9% | $138.76 | $144.94 | +4.45% |
| ▼ Q1 FY2025 | Feb 6, 2025 | -53.6% | $134.67 | $151.50 | +12.50% |
| ▼ Q4 FY2024 | Nov 12, 2024 | -55.1% | $126.80 | $128.41 | +1.27% |
| ▼ Q3 FY2024 | Jul 25, 2024 | -37.1% | $158.82 | $155.48 | -2.10% |
| ▼ Q2 FY2024 | Apr 25, 2024 | -26.7% | $135.35 | $146.05 | +7.91% |
Q1 FY2026+2.87%
Report Date
Feb 10, 2026
EPS Beat/Miss
—
Price Before
$188.01
Price After
$193.40
Q4 FY2025+2.26%
Report Date
Nov 6, 2025
EPS Beat/Miss
-29.3%
Price Before
$165.26
Price After
$169.00
Q3 FY2025+4.43%
Report Date
Jul 29, 2025
EPS Beat/Miss
-27.3%
Price Before
$144.10
Price After
$150.48
Q2 FY2025+4.45%
Report Date
Apr 29, 2025
EPS Beat/Miss
-13.9%
Price Before
$138.76
Price After
$144.94
Q1 FY2025+12.50%
Report Date
Feb 6, 2025
EPS Beat/Miss
-53.6%
Price Before
$134.67
Price After
$151.50
Q4 FY2024+1.27%
Report Date
Nov 12, 2024
EPS Beat/Miss
-55.1%
Price Before
$126.80
Price After
$128.41
Q3 FY2024-2.10%
Report Date
Jul 25, 2024
EPS Beat/Miss
-37.1%
Price Before
$158.82
Price After
$155.48
Q2 FY2024+7.91%
Report Date
Apr 25, 2024
EPS Beat/Miss
-26.7%
Price Before
$135.35
Price After
$146.05
Avg Miss Reaction+4.39%
Beat Rate0 / 8 quarters
Largest Move+12.50% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: AZNCF ends December
AstraZeneca PLC (AZNCF) most recently reported earnings on February 10, 2026 for Q1 FY2026, posting EPS of $1.49 (in line with the analyst consensus of —). The next AZNCF earnings date is expected around September 1, 2026.
Each quarter, investors track AZNCF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. AZNCF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
AZNCF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
AZNCF earnings · 4 questionsAstraZeneca PLC's next earnings report is expected around September 1, 2026. AZNCF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; AZNCF historically reports after market close (AMC).
AZNCF earnings datewhen is AZNCF earningsAZNCF next earnings datewhen does AZNCF report earningsAZNCF earnings calendar
▸ Source: FMP · AstraZeneca PLC SEC filings · US GAAP · AstraZeneca PLC SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026